Olympia Pharmaceuticals Strengthens National Presence, Bringing New Licensing to Mississippi




Olympia Pharmaceuticals Strengthens National Presence, Bringing New Licensing to Mississippi

The industry-leading 503B outsourcing facility grows its footprint to 49 states, offering expanded healthcare resources with a spotlight on Mississippi

ORLANDO, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) — Olympia Pharmaceuticals, a state-of-the-art, FDA-registered 503A and 503B pharmaceutical outsourcing facility, today announces its expansion into Mississippi after successfully obtaining licensing in the state. This is a significant step in its goal to support healthcare providers across the country as Olympia is now licensed in 49 states across the U.S.

Expanding Olympia’s national presence has been at the heart of the company’s vision since its inception. From day one, the company has remained steadfast in its commitment to making quality healthcare solutions accessible across the nation. This expansion is not just about growing Olympia’s footprint, but about ensuring that healthcare providers and patients in every corner of the country have access to the vital compounded treatment options they need.

“Achieving licensure in Mississippi is a significant milestone for us, and we are thrilled to be able to offer our services in this new market,” said Mark Mikhael, CEO of Olympia Pharmaceuticals. “This new licensing not only represents a key expansion for our company, but also reinforces our ongoing commitment to improving healthcare access. By providing patients in Mississippi with the medications they need, we’re taking another step towards our mission of ensuring that quality healthcare and essential treatments are available to individuals across the nation, no matter where they live.”

With its new presence in Mississippi, Olympia is poised to deliver reliable and quality compounded medication solutions to healthcare providers and their patients. Olympia understands the importance of healthcare solutions and has worked tirelessly to meet the diverse needs of different communities. The company’s unwavering dedication to this cause is what has driven its success and continues to fuel its efforts as it expands further into new markets, building partnerships, and delivering innovative treatments to those who need them most.

“This is what we always envisioned for Olympia. Being able to support the healthcare industry across the country was the mission from the start,” said Stan Loomis, co-founder of Olympia Pharmaceuticals. “This licensure is important for not only healthcare providers and pharmacies in Mississippi, but for the patients as well. Allowing patients to have access to compounded medication is critical for their personal well-being.”

If you are a healthcare provider in Mississippi, visit www.olympiapharmacy.com to learn more about Olympia Pharmaceuticals’ product offerings and how it can support your practice with compounded medications.

About Olympia Pharmaceuticals
Olympia Pharmaceuticals is a state-of-the-art, FDA-registered 503B pharmaceutical outsourcing facility and 503A pharmacy supporting both patient-specific and office-use needs across the U.S. Co-founded by Stan and Naomi Loomis, the team is made up of pharmacy technicians, pharmacists, quality personnel, and engineers, creating an educated and experienced staff knowledgeable in all facets of pharmacy production. As an FDA-registered outsourcing facility, Olympia offers compounded medications to 48 states for both office use and patient prescriptions. Olympia specializes in weight loss, dermatology, IV nutritional therapy, erectile dysfunction, and more.

Media Contact
Daniele Spring
Uproar by Moburst for Olympia Pharmaceuticals
daniele.spring@moburst.com

Sevaro Health Named to the 2025 CB Insights’ List of the 50 Most Promising Digital Health Startups




Sevaro Health Named to the 2025 CB Insights’ List of the 50 Most Promising Digital Health Startups

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) — CB Insights named Sevaro Health to its seventh annual Digital Health 50, showcasing the 50 most promising private digital health companies in the world.

“The 2025 Digital Health 50 winners are high-momentum companies poised to define the next era of healthcare,” said Ellen Knapp, Principal Analyst at CB Insights. “This year’s cohort is advancing the shift from reactive to proactive care, developing AI solutions tailored to healthcare’s unique regulatory environment, and addressing critical sector-wide challenges from care access to provider burnout and workforce shortages.”

Powered by Synapse AI, Sevaro has built a system that integrates virtual neurologists directly with hospital teams to streamline workflows, reduce documentation fatigue, and deliver real-time insights that improve patient outcomes. Sevaro’s industry-leading 45-second response times ensures stroke patients receive expert care when every second counts.

“Being named to the CB Insights Digital Health 50 is a tremendous honor and a testament to the relentless work our team has put in over the past 6 years” said Rajiv Narula, M.D., CEO and Founder of Sevaro. “At Sevaro, we’ve been redefining teleneurology by fusing cutting-edge technology with seamless clinical collaboration. As a physician-led organization, we’re proud to combine clinical expertise with innovation to help hospitals elevate neurological care, optimize operations, and ultimately save lives.”

The CB Insights list primarily includes early and mid-stage startups driving innovation across digital health including: Nabla, Ambience, Hippocratic AI, Neko and RadAI. The organization picked winning companies based on CB Insights datasets, including deal activity, industry partnerships, team strength, investor strength, employee headcount, and proprietary Commercial Maturity and Mosaic scores, where Sevaro is in the top 1%. CB Insights also dug into Analyst Briefings submitted directly by startups.

Quick facts on the 2025 Digital Health 50:

• The 50 winners span categories such as care delivery, revenue cycle management, drug discovery & development, and diagnostics.
• This year’s cohort is deploying AI across a wide variety of use cases, with notable adoption of agentic AI, voice AI, and automated provider workflows.
• Collectively raised $2B in equity funding in 2025 YTD (as of 10/14/2025).
• 52% are early-stage companies (seed/angel or Series A funding).
• Established 140+ business relationships since 2024 with industry leaders including Cleveland Clinic, IBM, and Novartis.

About CB Insights

CB Insights is the leader in predictive intelligence on private companies. It delivers instant insights that help you source and analyze private companies, focus on the right markets, and stay ahead of competitors. Our AI agents are powerful because they translate signals into the exact outputs your teams need to move first — defensible, sourced, and board-ready. To learn more, please visit www.cbinsights.com. 

About Sevaro

Sevaro Health is a physician-led virtual neurology company delivering comprehensive care across the neurological journey. Through its Synapse AI platform, Sevaro partners with hospitals nationwide to expand access to neuroscience services, improve outcomes, and support long-term financial sustainability.

Rooted in the Sanskrit word Seva, meaning selfless service, Sevaro is committed to being the best place for neurologists to work and the most reliable partner for hospitals building the future of specialty care. To learn more, please visit www.sevaro.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2bae9435-223f-4056-86fc-321de15685ee

CONTACT: Press Contact:

John Ricks
Senior Marketing Manager,
Sevaro Health
John@Sevaro.com

Sharecare awarded three-year NCQA Accreditation for Wellness and Health Promotion




Sharecare awarded three-year NCQA Accreditation for Wellness and Health Promotion

Accreditation for its lifestyle and disease management interventions complements Sharecare’s existing three-year NCQA accreditations for Population Health Program and Case Management

ATLANTA, Oct. 28, 2025 (GLOBE NEWSWIRE) — Sharecare, the health tech company that helps to improve care quality, drive better outcomes, and lower costs across the healthcare ecosystem, today announced it has again received a three-year Wellness and Health Promotion (WHP) Accreditation by the National Committee for Quality Assurance (NCQA). With Sharecare voluntarily participating in NCQA’s nationally recognized evaluation of its lifestyle and disease management interventions, including its coaching programs and RealAge health risk assessment, three-year accreditation is the highest Accreditation status awarded by NCQA, demonstrating Sharecare’s strong performance of NCQA’s rigorous standards for wellness and health promotion programs.

“Maintaining three of the highest NCQA accreditations reflects Sharecare’s unwavering commitment to excellence and validates our delivery of high-quality, evidence-based care and our dedication to continuous improvement,” said Michelle Snyder, DNP, MSN, vice president of clinical strategy and solutions at Sharecare. “Demonstrating that we meet rigorous national standards, these top-tier recognitions also build trust with patients, providers, payors, and regulators, and enhance our credibility with commercial clients, health plans, and government programs.”

NCQA WHP Accreditation uses standardized program measures that allow employers to make informed comparisons when choosing among several wellness vendors, and comprehensively evaluates key areas of health promotion, including how wellness programs are implemented in the workplace; how services such as health coaching are provided to help eligible individuals develop skills to make healthy choices; and how sensitive health information of eligible individuals is properly safeguarded.

“NCQA’s Wellness & Health Promotion Accreditation requires organizations to demonstrate their compliance with well-defined standards and quality measures,” said Margaret E. O’Kane, NCQA President. “The NCQA seal will provide employers and consumers with the information they need to choose the best program in their markets.”

Conducted by a team of experts, WHP Accreditation surveys include rigorous on-site and off-site evaluations of 12 standards, which are purposely set high and intended to help wellness and health promotion organizations achieve the highest level of performance possible, increase healthy behavior change in eligible individuals, and create an environment of continuous improvement.

Sharecare’s NCQA Wellness and Health Promotion Accreditation is in addition to the three-year NCQA Population Health Program Accreditation it received in November 2024 for its platform, including programs for asthma, chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), coronary artery disease (CAD), diabetes, and hypertension; as well as the three-year NCQA Case Management Accreditation it received in April 2024 for its complex case management capabilities available through its whole health advocacy solution. Notably, Sharecare bears the distinction of being only one of three companies to hold those three-year NCQA Accreditations simultaneously.

For more information on Sharecare’s NCQA-accredited health and well-being platform and programs, including its lifestyle and disease management interventions, email the team at connect@sharecare.com.

About NCQA
NCQA is a private, nonprofit organization dedicated to improving health care quality. NCQA accredits and certifies a wide range of health care organizations. It also recognizes clinicians and practices in key areas of performance. NCQA’s Healthcare Effectiveness Data and Information Set (HEDIS®) is the most widely used performance measurement tool in health care. NCQA’s website (ncqa.org) contains information to help consumers, employers and others make more informed health care choices. NCQA can be found online at ncqa.org, on Twitter @ncqa, on Facebook at facebook.com/NCQA.org/ and on LinkedIn at linkedin.com/company/ncqa.

About Sharecare
Sharecare is a digital healthcare company that delivers software and tech-enabled services to stakeholders across the healthcare ecosystem to help improve care quality, drive better outcomes, and lower costs. Through its data-driven AI insights, evidence-based resources, and comprehensive platform – including benefits navigation, care management, home care resources, health information management, and more – Sharecare helps people easily and efficiently manage their healthcare and improve their well-being. Across its three business channels, Sharecare enables health plan sponsors, health systems and physician practices, and leading pharmaceutical brands to drive personalized and value-based care at scale. To learn more, visit www.sharecare.com.

Media Contact:
Sharecare PR Team
PR@sharecare.com

Avance Clinical Unveils Dedicated CNS Center of Excellence for Expert Clinical Trial Services in Neuroscience




Avance Clinical Unveils Dedicated CNS Center of Excellence for Expert Clinical Trial Services in Neuroscience

ADELAIDE, Australia, Oct. 28, 2025 (GLOBE NEWSWIRE) — Avance Clinical, the award-winning Australian led, global CRO built exclusively to service the clinical research needs of biotech companies, today announced the launch of its Center of Excellence dedicated to central nervous system (CNS) disorders. This strategic initiative addresses the unique clinical trial execution challenges facing biotech companies developing neurological therapies, offering integrated solutions from first-in-human studies through Phase III trials.

Building on more than 50 completed CNS trials over the last five years, the center aims to help biotech developers tackle critical operational bottlenecks including complex protocol requirements, challenging patient recruitment, and elevated screen failure rates that average 57% in CNS trials compared to 36.3% across other therapeutic areas.

Comprehensive CNS-Focused Services
The center provides end-to-end support including CNS-specific protocol design, regulatory strategy across multiple jurisdictions, specialized site networks, targeted patient recruitment strategies, and advanced data management and analysis for complex CNS endpoints.

Distinguished Leadership
Leading the center is Dr. Francesco Bibbiani, whose appointment as Vice President & Therapeutic Area Head, CNS Center of Excellence represents a significant strategic acquisition. Bibbiani brings over 25 years of CNS clinical development experience from senior leadership roles at Neurogene, Dyne Therapeutics, Ultragenyx, PTC Therapeutics, and Eisai Inc. His expertise spans Phase I through pivotal trials across multiple CNS conditions including Parkinson’s disease, Huntington’s disease, neuromuscular disorders, and epilepsy, complemented by board certification in neurology and 25+ peer-reviewed publications.

“CNS drug development presents complex clinical trial challenges, particularly for biotech companies with innovative mechanisms and constrained resources,” said Bibbiani. “Our center integrates specialized CNS clinical expertise with proven operational excellence, enabling sponsors to execute high-quality trials efficiently from first-in-human studies through pivotal Phase III programs.”

Strategic Partnership Model
Designed exclusively for biotech companies, the center operates as a true partnership that strategically incorporates Australia’s unparalleled regulatory advantages across all trial designs. Whether conducting early phase studies exclusively in Australia or managing global multi-regional trials, the center maximizes the Australian advantage through accelerated startup timelines, streamlined regulatory pathways, and strategic program structuring that optimizes the 43.5% R&D tax incentive. This approach transforms Australia’s unique benefits into competitive advantages for both Australia-only early phase trials and international late phase programs spanning multiple geographies.

Key Differentiators
Avance Clinical’s key differentiators include exclusive biotech focus across all trial phases, involving thorough program analyses and strategic advice by subject matter experts through specialized centers of excellence, in-house regulatory affairs teams, access to over 2,000 specialized clinical sites globally, and proprietary GlobalReady process enabling seamless transition from early phase Australian studies to multi-regional late phase programs.

About Avance Clinical
Avance Clinical is the largest premium full-service Australian headquartered CRO delivering high-quality clinical trials in Australia, New Zealand, Asia, North America and Europe for international biotechs. The company has won multiple Frost & Sulivan CRO Market Leadership and Customer Value Leadership Awards. With over 30 years of experience and deep expertise across more than 250 indications, Avance Clinical provides services from pre-clinical to late phase trials, supported by best-in-class regulatory, clinical and operational expertise.

Find out more:

• Visit our website to find out more or request a proposal www.avancecro.com
• Find out more about the CNS Center of Excellence
• Get your CNS molecule GlobalReady with Avance Clinical
• Book a Meeting with our expert team
• Meet Avance Clinical at upcoming conferences

CONTACT
Gabe Martinez
Director Content, Media & PR
308-237-5567
Pr@scorrmarketing.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/54b00624-bed6-4c08-869b-15aaa69c303b

Bavarian Nordic Provides Further Support to Mpox Outbreak in Africa through Additional Donation of Vaccines




Bavarian Nordic Provides Further Support to Mpox Outbreak in Africa through Additional Donation of Vaccines

COPENHAGEN, Denmark, October 28, 2025 – Bavarian Nordic announced today a donation of mpox vaccines to Africa CDC to support the response to the ongoing mpox outbreak in Africa.

The donation of 110,000 doses of the vaccine has been allocated to Uganda in coordination with the key partners involved in the mpox Access and Allocation Mechanism (AAM), significantly increasing the availability of vaccines in the country, which has reported the second-highest number of cases of mpox in Africa in 2025. The vaccines were delivered to Uganda earlier this week.

Paul Chaplin, President & CEO of Bavarian Nordic, said: “Mpox remains a health emergency in Africa as evidenced by the continued spread across the continent and increase in number of cases. The continued availability of funding and vaccines is critical for a successful public health response, and we are pleased to reinforce our commitment through another donation of our mpox vaccine.”

H.E. Dr. Jean Kaseya, Director-General of Africa CDC, said: “Africa CDC welcomes this continued partnership with Bavarian Nordic in responding to the ongoing mpox outbreak. This donation of vaccines will significantly strengthen Uganda’s outbreak response and supports our collective efforts to ensure timely and equitable access to life-saving tools across Africa. Sustained collaboration with our partners is vital to achieving a continent that is prepared, self-reliant, and resilient against public health threats.”

With this donation, Bavarian Nordic has committed a total of 165,000 doses of the MVA-BN vaccine to Africa. The Company previously donated doses to the European Commission’s Health Emergency Preparedness and Response Authority (HERA) and GAVI eligible countries as part of a joint response to mpox outbreak.

About the mpox vaccine
MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic is the only non-replicating mpox vaccine approved in the U.S., Switzerland, Singapore and Mexico (marketed as JYNNEOS^®), Canada (marketed as IMVAMUNE^®), and the EU/EAA and United Kingdom (marketed as IMVANEX^®). Originally developed as a smallpox vaccine in collaboration with the U.S. government to ensure the supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines, MVA-BN has been indicated for use in the general population in individuals considered at risk for smallpox or mpox infection.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com.

Contact media:
Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03

Attachment

• 2025-10-28-en

Swarm Oncology announces research collaboration with a leading hospital to advance T cell therapies for advanced solid cancers




Swarm Oncology announces research collaboration with a leading hospital to advance T cell therapies for advanced solid cancers

London, United Kingdom October 28, 2025, Swarm Oncology Ltd. (“Swarm Oncology” or “Swarm”), a biotechnology company pioneering novel T cell therapies to achieve long-term remission in patients with advanced solid cancers, is pleased to announce a research collaboration with a leading US clinic to further broaden the feasibility and manufacturing of research-scale Swarm-T cell preparations by using samples from patients treated in the clinic’s cancer vaccine studies. This research collaboration further expands Swarm’s dedicated efforts in advancing its novel T cell therapy targeting advanced solid cancers.

Despite advances in cancer treatment, solid cancers remain a leading cause of death worldwide, with significant unmet need in improving survival outcomes. Cancer vaccines have shown promise by stimulating patients’ immune systems to attack cancerous cells, however, their impact has been limited to date due to barriers of efficacy and an inability to frequently generate a sufficiently strong or high-quality immune response on their own.

Swarm’s breakthrough T cell platform is designed to overcome these limitations by significantly enhancing the effectiveness of cancer vaccines. Swarm’s platform amplifies patients’ immune response to cancer vaccines, potentially offering a new path towards durable remission in solid cancers.

Under the agreement, the collaborating clinic will provide patient blood samples together with immune response data, from cancer patients who have received its cancer antigen vaccination. Swarm will use these materials to assess the phenotypic and antigen-specific T cell responses and when appropriate, manufacture research scale products.

Martin Olin, CEO of Swarm, said: “This collaboration is an important step in further validating our platform’s ability to manufacture personalized T-cell therapies from patients with existing anti-tumour immune responses. By demonstrating feasibility with patient samples, we’re addressing the growing demand for cancer immunotherapies that can overcome the historic limitations of cancer vaccines alone.”

The two-part feasibility study will begin with comprehensive immune profiling to assess T cell populations and antigen-specific responses in patients who have received the cancer vaccine. If predefined criteria are met, the second part will focus on the research-scale manufacture of Swarm-T preparations, which will then be evaluated against key functional and quality benchmarks.

About Swarm Oncology

Swarm Oncology is developing novel potent T cell therapies which are designed to overcome major shortcomings of immunotherapy approaches with the goal to drive solid cancers to complete remission.

For further information, contact:

Swarm Oncology
info@swarmoncology.bio

ICR Healthcare
Mary-Jane Elliott, Davide Salvi, Emily Johnson
SwarmOncology@icrhealthcare.com

Bavarian Nordic Provides Further Support to Mpox Outbreak in Africa through Additional Donation of Vaccines




Bavarian Nordic Provides Further Support to Mpox Outbreak in Africa through Additional Donation of Vaccines

COPENHAGEN, Denmark, October 28, 2025 – Bavarian Nordic announced today a donation of mpox vaccines to Africa CDC to support the response to the ongoing mpox outbreak in Africa.

The donation of 110,000 doses of the vaccine has been allocated to Uganda in coordination with the key partners involved in the mpox Access and Allocation Mechanism (AAM), significantly increasing the availability of vaccines in the country, which has reported the second-highest number of cases of mpox in Africa in 2025. The vaccines were delivered to Uganda earlier this week.

Paul Chaplin, President & CEO of Bavarian Nordic, said: “Mpox remains a health emergency in Africa as evidenced by the continued spread across the continent and increase in number of cases. The continued availability of funding and vaccines is critical for a successful public health response, and we are pleased to reinforce our commitment through another donation of our mpox vaccine.”

H.E. Dr. Jean Kaseya, Director-General of Africa CDC, said: “Africa CDC welcomes this continued partnership with Bavarian Nordic in responding to the ongoing mpox outbreak. This donation of vaccines will significantly strengthen Uganda’s outbreak response and supports our collective efforts to ensure timely and equitable access to life-saving tools across Africa. Sustained collaboration with our partners is vital to achieving a continent that is prepared, self-reliant, and resilient against public health threats.”

With this donation, Bavarian Nordic has committed a total of 165,000 doses of the MVA-BN vaccine to Africa. The Company previously donated doses to the European Commission’s Health Emergency Preparedness and Response Authority (HERA) and GAVI eligible countries as part of a joint response to mpox outbreak.

About the mpox vaccine
MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic is the only non-replicating mpox vaccine approved in the U.S., Switzerland, Singapore and Mexico (marketed as JYNNEOS^®), Canada (marketed as IMVAMUNE^®), and the EU/EAA and United Kingdom (marketed as IMVANEX^®). Originally developed as a smallpox vaccine in collaboration with the U.S. government to ensure the supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines, MVA-BN has been indicated for use in the general population in individuals considered at risk for smallpox or mpox infection.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com.

Contact media:
Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03

Attachment

• 2025-10-28-en

Swarm Oncology announces research collaboration with a leading hospital to advance T cell therapies for advanced solid cancers




Swarm Oncology announces research collaboration with a leading hospital to advance T cell therapies for advanced solid cancers

London, United Kingdom October 28, 2025, Swarm Oncology Ltd. (“Swarm Oncology” or “Swarm”), a biotechnology company pioneering novel T cell therapies to achieve long-term remission in patients with advanced solid cancers, is pleased to announce a research collaboration with a leading US clinic to further broaden the feasibility and manufacturing of research-scale Swarm-T cell preparations by using samples from patients treated in the clinic’s cancer vaccine studies. This research collaboration further expands Swarm’s dedicated efforts in advancing its novel T cell therapy targeting advanced solid cancers.

Despite advances in cancer treatment, solid cancers remain a leading cause of death worldwide, with significant unmet need in improving survival outcomes. Cancer vaccines have shown promise by stimulating patients’ immune systems to attack cancerous cells, however, their impact has been limited to date due to barriers of efficacy and an inability to frequently generate a sufficiently strong or high-quality immune response on their own.

Swarm’s breakthrough T cell platform is designed to overcome these limitations by significantly enhancing the effectiveness of cancer vaccines. Swarm’s platform amplifies patients’ immune response to cancer vaccines, potentially offering a new path towards durable remission in solid cancers.

Under the agreement, the collaborating clinic will provide patient blood samples together with immune response data, from cancer patients who have received its cancer antigen vaccination. Swarm will use these materials to assess the phenotypic and antigen-specific T cell responses and when appropriate, manufacture research scale products.

Martin Olin, CEO of Swarm, said: “This collaboration is an important step in further validating our platform’s ability to manufacture personalized T-cell therapies from patients with existing anti-tumour immune responses. By demonstrating feasibility with patient samples, we’re addressing the growing demand for cancer immunotherapies that can overcome the historic limitations of cancer vaccines alone.”

The two-part feasibility study will begin with comprehensive immune profiling to assess T cell populations and antigen-specific responses in patients who have received the cancer vaccine. If predefined criteria are met, the second part will focus on the research-scale manufacture of Swarm-T preparations, which will then be evaluated against key functional and quality benchmarks.

About Swarm Oncology

Swarm Oncology is developing novel potent T cell therapies which are designed to overcome major shortcomings of immunotherapy approaches with the goal to drive solid cancers to complete remission.

For further information, contact:

Swarm Oncology
info@swarmoncology.bio

ICR Healthcare
Mary-Jane Elliott, Davide Salvi, Emily Johnson
SwarmOncology@icrhealthcare.com

Novartis announces expiration of Tourmaline Bio tender offer 




Novartis announces expiration of Tourmaline Bio tender offer 

Basel, October 28 2025 – Novartis today announced that its previously announced tender offer (the “offer”) by Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48.00 per Share, in cash, without interest and subject to any applicable withholding, expired at one minute following 11:59 p.m., Eastern Time, on October 27, 2025 (the “Expiration Date”).  

Computershare Trust Company, N.A., the depositary for the offer, has advised that, as of the Expiration Date, approximately 24,030,382 Shares were validly tendered and not validly withdrawn pursuant to the offer, representing approximately 92.94% of the issued and outstanding Shares immediately prior to the Expiration Date. 
  
The parties expect the transaction to close on October 28, 2025, promptly following the acceptance of all Shares validly tendered and not validly withdrawn pursuant to the offer. 

Disclaimer 
This press release contains statements that are not statements of historical fact, or “forward-looking statements,” including with respect to Novartis’s proposed acquisition of Tourmaline. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Tourmaline’s product candidates, Tourmaline’s platform, the proposed acquisition of Tourmaline and the expected timetable for completing the proposed acquisition, the benefits sought to be achieved in the proposed acquisition, or potential future revenues from Tourmaline’s product candidates. You should not place undue reliance on these statements. Such forward-looking statements are based on Novartis’s current beliefs and expectations regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that clinical trials for any of Tourmaline’s product candidates will be successful, that Tourmaline’s approach to the discovery and development of product candidates based on its AOC™ platform will produce any products of commercial value, that any of Tourmaline’s product candidates will be submitted for marketing approval or approved for sale or, if approved, receive approval for any additional indications or labeling, in any market, or at any particular time, nor can there be any guarantee that, if approved, any of Tourmaline’s product candidates will be commercially successful in the future. Neither can there be any guarantee that the conditions to the closing of the proposed acquisition will be satisfied on the expected timetable or at all or that the expected benefits or synergies from this transaction will be achieved in the expected timeframe, or at all. In particular, expectations regarding Tourmaline or the transaction described in this press release could be affected by, among other things, the satisfaction of customary closing conditions; the risk that competing offers or acquisition proposals will be made; the effects of disruption from the transactions contemplated by the Merger Agreement and the impact of the announcement and pendency of the transactions on Novartis and/or Tourmaline’s businesses, including their relationships with employees, business partners or governmental entities; the risk that the offer or the merger may be more expensive to complete than anticipated; the risk that stockholder litigation in connection with the offer or the merger may result in significant costs of defense, indemnification and liability; a diversion of management’s attention from ongoing business operations and opportunities as a result of the offer, the merger or otherwise; general industry conditions and competition; general political, economic and business conditions, including interest rate and currency exchange rate fluctuations; the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s and Tourmaline’s filings and reports with the SEC, including Novartis AG’s Annual Report on Form 20-F for the year ended December 31, 2024, Tourmaline’s Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, and any subsequent filings made by either party with the SEC, available on the SEC’s website at www.sec.gov. Novartis is providing the information in this press release as of this date, and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, except to the extent required by law. 

About Novartis  
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. 

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. 

# # # 

Novartis announces expiration of Tourmaline Bio tender offer 




Novartis announces expiration of Tourmaline Bio tender offer 

Basel, October 28 2025 – Novartis today announced that its previously announced tender offer (the “offer”) by Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48.00 per Share, in cash, without interest and subject to any applicable withholding, expired at one minute following 11:59 p.m., Eastern Time, on October 27, 2025 (the “Expiration Date”).  

Computershare Trust Company, N.A., the depositary for the offer, has advised that, as of the Expiration Date, approximately 24,030,382 Shares were validly tendered and not validly withdrawn pursuant to the offer, representing approximately 92.94% of the issued and outstanding Shares immediately prior to the Expiration Date. 
  
The parties expect the transaction to close on October 28, 2025, promptly following the acceptance of all Shares validly tendered and not validly withdrawn pursuant to the offer. 

Disclaimer 
This press release contains statements that are not statements of historical fact, or “forward-looking statements,” including with respect to Novartis’s proposed acquisition of Tourmaline. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Tourmaline’s product candidates, Tourmaline’s platform, the proposed acquisition of Tourmaline and the expected timetable for completing the proposed acquisition, the benefits sought to be achieved in the proposed acquisition, or potential future revenues from Tourmaline’s product candidates. You should not place undue reliance on these statements. Such forward-looking statements are based on Novartis’s current beliefs and expectations regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that clinical trials for any of Tourmaline’s product candidates will be successful, that Tourmaline’s approach to the discovery and development of product candidates based on its AOC™ platform will produce any products of commercial value, that any of Tourmaline’s product candidates will be submitted for marketing approval or approved for sale or, if approved, receive approval for any additional indications or labeling, in any market, or at any particular time, nor can there be any guarantee that, if approved, any of Tourmaline’s product candidates will be commercially successful in the future. Neither can there be any guarantee that the conditions to the closing of the proposed acquisition will be satisfied on the expected timetable or at all or that the expected benefits or synergies from this transaction will be achieved in the expected timeframe, or at all. In particular, expectations regarding Tourmaline or the transaction described in this press release could be affected by, among other things, the satisfaction of customary closing conditions; the risk that competing offers or acquisition proposals will be made; the effects of disruption from the transactions contemplated by the Merger Agreement and the impact of the announcement and pendency of the transactions on Novartis and/or Tourmaline’s businesses, including their relationships with employees, business partners or governmental entities; the risk that the offer or the merger may be more expensive to complete than anticipated; the risk that stockholder litigation in connection with the offer or the merger may result in significant costs of defense, indemnification and liability; a diversion of management’s attention from ongoing business operations and opportunities as a result of the offer, the merger or otherwise; general industry conditions and competition; general political, economic and business conditions, including interest rate and currency exchange rate fluctuations; the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s and Tourmaline’s filings and reports with the SEC, including Novartis AG’s Annual Report on Form 20-F for the year ended December 31, 2024, Tourmaline’s Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, and any subsequent filings made by either party with the SEC, available on the SEC’s website at www.sec.gov. Novartis is providing the information in this press release as of this date, and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, except to the extent required by law. 

About Novartis  
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. 

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. 

# # #